Literature DB >> 16283443

Aggressive vestibular schwannomas showing postoperative rapid growth - their association with decreased p27 expression.

Ho Jun Seol1, Hee-Won Jung, Sung-Hye Park, Sung-Kyun Hwang, Dong Gyu Kim, Sun Ha Paek, Young-Seob Chung, Chang Sub Lee.   

Abstract

Vestibular schwannomas (VSs) are relatively slow growing tumors. However, some rapidly regrow or recur after surgical resection. The objective of this study was to identify those molecular characteristics predicting rapid recurrence after surgical resection. Immunohistochemically determined expressions of several cell cycle regulators and apoptosis-associated proteins in 12 cases of aggressive VS (AVS) and in 15 control cases of usual VS (UVS) cases were compared. The expressions of p53 and Bax (pro-apoptotic protein), Bcl-2 (anti-apoptotic protein), Fas, and Fas-L (apoptotic death receptor and ligand), caspase 3 (apoptotic effector caspase proteins), and p27 and p21 (cyclin-dependent kinase inhibitors) were analyzed using tissue array blocks. Loss of p27 expression was observed in 8 of 12 AVS cases (67%) and in 3 UVS cases (20%); p21 was expressed in all cases. Loss of Bax was observed in 3 AVS and 3 UVS cases. The anti-apoptotic protein, Bcl-2, was expressed in 9 AVS (75%) and 11 UVS (73%), and p53, Fas-L, and caspase 3 were negative and Fas was positive in all AVS and UVS cases. Of these, only the loss of p27 was statistically significant (P = 0.02). The loss of p27 in AVS may explain the unusually high proliferative potential of AVS versus UVS, and p27 may be a predictor of VS aggressiveness. The expressions of other apoptosis associated proteins were not significantly different in the two groups. This may be the first report to identify a molecular entity associated with aggressive VS. However, further studies are required.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16283443     DOI: 10.1007/s11060-005-2886-0

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  32 in total

1.  Frequent loss of the P16INK4a gene product in human pituitary tumors.

Authors:  M Woloschak; A Yu; J Xiao; K D Post
Journal:  Cancer Res       Date:  1996-06-01       Impact factor: 12.701

2.  Aberrant p27kip1 expression in endocrine and other tumors.

Authors:  R V Lloyd; L Jin; X Qian; E Kulig
Journal:  Am J Pathol       Date:  1997-02       Impact factor: 4.307

3.  Anti-sense oligonucleotide of p21(waf1/cip1) prevents interleukin 4-mediated elevation of p27(kip1) in low grade astrocytoma cells.

Authors:  J Liu; M L Estes; J A Drazba; H Liu; R Prayson; S Kondo; B S Jacobs; G H Barnett; B P Barna
Journal:  Oncogene       Date:  2000-02-03       Impact factor: 9.867

4.  Expression pattern of apoptotic markers in vestibular schwannomas.

Authors:  Christian Mawrin; Elmar Kirches; Knut Dietzmann; Albert Roessner; Carsten Boltze
Journal:  Pathol Res Pract       Date:  2002       Impact factor: 3.250

5.  Conservative management of acoustic neuroma in the elderly patient.

Authors:  H Silverstein; A McDaniel; H Norrell; J Wazen
Journal:  Laryngoscope       Date:  1985-07       Impact factor: 3.325

6.  Aggressive vestibular schwannomas with postoperative rapid growth: clinicopathological analysis of 15 cases.

Authors:  Sung-Kyun Hwang; Dong Gyu Kim; Sun Ha Paek; Chae-Yong Kim; Min Kyung Kim; Je G Chi; Hee-Won Jung
Journal:  Neurosurgery       Date:  2002-12       Impact factor: 4.654

7.  Retinoblastoma-cyclin-dependent kinase pathway deregulation in vestibular schwannomas.

Authors:  John M Lasak; D Bradley Welling; Elena M Akhmametyeva; Mariah Salloum; Long-Sheng Chang
Journal:  Laryngoscope       Date:  2002-09       Impact factor: 3.325

8.  Long-term follow-up of the residual intracanalicular tumours after subtotal removal of acoustic neurinomas.

Authors:  S Kameyama; R Tanaka; T Kawaguchi; Y Honda; H Yamazaki; A Hasegawa
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

9.  cDNA microarray analysis of vestibular schwannomas.

Authors:  D Bradley Welling; John M Lasak; Elena Akhmametyeva; Bobak Ghaheri; Long-Sheng Chang
Journal:  Otol Neurotol       Date:  2002-09       Impact factor: 2.311

10.  Increased expression of mutant forms of p53 oncogene in primary lung cancer.

Authors:  R Iggo; K Gatter; J Bartek; D Lane; A L Harris
Journal:  Lancet       Date:  1990-03-24       Impact factor: 79.321

View more
  3 in total

1.  Preclinical validation of anti-nuclear factor-kappa B therapy to inhibit human vestibular schwannoma growth.

Authors:  Sonam Dilwali; Martijn C Briët; Shyan-Yuan Kao; Takeshi Fujita; Lukas D Landegger; Michael P Platt; Konstantina M Stankovic
Journal:  Mol Oncol       Date:  2015-03-31       Impact factor: 6.603

2.  YAP-Mediated Recruitment of YY1 and EZH2 Represses Transcription of Key Cell-Cycle Regulators.

Authors:  Sany Hoxha; Alyssa Shepard; Scott Troutman; Huitian Diao; Joanne R Doherty; Michalina Janiszewska; Robert M Witwicki; Matthew E Pipkin; William W Ja; Michael S Kareta; Joseph L Kissil
Journal:  Cancer Res       Date:  2020-05-14       Impact factor: 12.701

3.  Robot-assisted resection of paraspinal Schwannoma.

Authors:  Moon Sool Yang; Keung Nyun Kim; Do Heum Yoon; William Pennant; Yoon Ha
Journal:  J Korean Med Sci       Date:  2010-12-22       Impact factor: 2.153

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.